Find in Library

Multiple myeloma (MM) first-line treatment algorithms include immuno-chemotherapy (ICT) induction, high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) consolidation, followed by lenalidomide maintenance. After these initial therapies, most patients suffer a disease relapse and require subsequent treatment lines including ICT, additional HDCT and ASCT, or novel immunotherapies. The presence of somatic mutations in peripheral blood cells has been associated with adverse outcomes in a variety of hematological malignancies. Nonsense and frameshift mutations in the <i>PPM1D</i> gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to the gain-of-function of Wip1 phosphatase, which may impair the p53-dependent G1 checkpoint and promote cell proliferation. Here, we determined the presence of <i>PPM1D</i> gene mutations in peripheral blood cells of 75 subsequent myeloma patients in remission after first or second HDCT/ASCT. The prevalence of truncating <i>PPM1D</i> gene mutations emerged at 1.3% after first HDCT/ASCT, and 7.3% after second HDCT/ASCT, with variant allele frequencies (VAF) of 0.01 to 0.05. Clinical outcomes were inferior in the <i>PPM1D</i>-mutated (<i>PPM1D</i>mut) subset with median progression-free survival (PFS) of 15 vs. 37 months (<i>p</i> = 0.0002) and median overall survival (OS) of 36 vs. 156 months (<i>p</i> = 0.001) for the <i>PPM1D</i>mut and <i>PPM1D</i>wt population, respectively. Our data suggest that the occurrence of <i>PPM1D</i> gene mutations in peripheral blood cells correlates with inferior outcomes after ASCT in patients with multiple myeloma.